Clinical trials: Endocrine Therapy
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-Pump-2 (NCT03830281)
- Testing
- Ultra-Rapid Lispro, Insulin Lispro
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
The purpose of this study is to evaluate the efficacy of a new dose of 500mg Fulvestrant with the standard dose of 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a…
- Trial name
- NCT01300351
- Testing
- Fulvestrant
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer
A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .
- Trial name
- NCT06755359
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 12 sites in France
- Volunteers
- 40 people
- Sponsor
- Alpha Tau Medical LTD.
Type 2 Diabetes Mellitus
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
- Trial name
- NCT01196546
- Testing
- vildagliptin/metformin
- Where
- 8 sites in Thailand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis
Locally Advanced Pancreatic Adenocarcinoma
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
- Trial name
- ENACT (NCT06850623)
- Testing
- Acoustic Cluster Therapy, Modified FOLFIRINOX
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- EXACT Therapeutics AS
Cancer, Ovarian Cancer
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy.
- Trial name
- NCT00523380
- Testing
- recombinant interleukin-21, caelyx (pegylated liposomal doxorubicin)
- Where
- 7 sites in France, Germany
- Volunteers
- 10 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
DOMME Dose Optimization Multicentric Mexican Evaluation
To evaluate the efficiency of Lantus plus combined oral hypoglycaemic agents in terms of respondents percentage. The respondent is defined as the person achieving a value in the final determination of HbA1c < 7% as its absolute…
- Trial name
- DOMME (NCT00488527)
- Testing
- Insulin glargine
- Where
- Mexico
- Volunteers
- 371 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in…
- Trial name
- NCT01486966
- Testing
- insulin detemir, insulin aspart, insulin NPH
- Where
- 6 sites in China
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Growth Disorders
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France
This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in France and…
- Trial name
- ECOS FRA (NCT01291394)
- Testing
- Easypod™
- Where
- France
- Volunteers
- 223 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ovarian Cancer
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR.
- Trial name
- NCT00073541
- Testing
- EMD 72000
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- EMD Serono
Non-small Cell Lung Cancer, Colorectal Cancer
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 5,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the…
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
- Trial name
- NCT04638751
- Testing
- Immunotherapy, Chemotherapy, CRC surgical resection
- Where
- 10 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Center-involved Diabetic Macular Edema (CI-DME)
Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema
This study will evaluate the effects of add-on carotenoid plus anti-oxidant nutritional supplementation to standard anti-vascular endothelial growth factor therapy for subjects with center-involved diabetic macular edema
- Trial name
- PROACTIVEDME (NCT03866005)
- Testing
- Diabetes Visual Function Study (DiVFuSS) softgels
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- ZeaVision, LLC
Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without…
- Trial name
- RAINFOL™-07 (NCT07564141)
- Testing
- Rina-S, Bevacizumab, Carboplatin
- Where
- 9 sites in United States, Japan
- Volunteers
- 688 people
- Sponsor
- Genmab
Diabetic Neuropathies
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy and safety of pregabalin administered twice a day compared to placebo in reducing pain in subjects with painful diabetic peripheral neuropathy.
- Trial name
- NCT00143156
- Testing
- pregabalin
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.